1. Home
  2. UFI vs BMEA Comparison

UFI vs BMEA Comparison

Compare UFI & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unifi Inc. New

UFI

Unifi Inc. New

HOLD

Current Price

$3.14

Market Cap

84.6M

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.24

Market Cap

96.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UFI
BMEA
Founded
1969
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.6M
96.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
UFI
BMEA
Price
$3.14
$1.24
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.71
AVG Volume (30 Days)
77.2K
1.4M
Earning Date
11-04-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$559,646,000.00
N/A
Revenue This Year
$4.14
N/A
Revenue Next Year
$9.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.96
$0.87
52 Week High
$6.49
$6.79

Technical Indicators

Market Signals
Indicator
UFI
BMEA
Relative Strength Index (RSI) 33.48 50.11
Support Level $2.96 $0.95
Resistance Level $3.60 $1.12
Average True Range (ATR) 0.21 0.11
MACD 0.03 0.03
Stochastic Oscillator 26.56 59.19

Price Performance

Historical Comparison
UFI
BMEA

About UFI Unifi Inc. New

Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: